Cladribine monotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma

Yasuhiro Nakashima, Toshihiro Shimada, Y. Yamada, Ilseung Choi, Yuji Yufu, Naokuni Uike

Research output: Contribution to journalArticle

Abstract

Cladribine is a purine analogue that is resistant to degradation by adenosine deaminase. We describe the efficacy of cladribine monotherapy in 8 patients with relapsed or refractory indolent non-Hodgkin lymphoma. The median age of the patients was 57 years. All patients were given 1-3 courses of cladribine monotherapy at 0.09 mg/kg/day continuous infusion for 7 days. Although all patients had been treated with rituximab and CHOP-like regimens, the response rate was excellent (85.7%). Thus we consider that cladribine is the first treatment of choice in the patients with relapsed or refractory indolent lymphoma.

Original languageEnglish
Pages (from-to)568-570
Number of pages3
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume45
Issue number7
Publication statusPublished - Jan 1 2004
Externally publishedYes

Fingerprint

Cladribine
Non-Hodgkin's Lymphoma
Adenosine Deaminase
Lymphoma

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Cladribine monotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma. / Nakashima, Yasuhiro; Shimada, Toshihiro; Yamada, Y.; Choi, Ilseung; Yufu, Yuji; Uike, Naokuni.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 45, No. 7, 01.01.2004, p. 568-570.

Research output: Contribution to journalArticle

Nakashima, Yasuhiro ; Shimada, Toshihiro ; Yamada, Y. ; Choi, Ilseung ; Yufu, Yuji ; Uike, Naokuni. / Cladribine monotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2004 ; Vol. 45, No. 7. pp. 568-570.
@article{e4d18a89edf04928af325ff2f5fb81eb,
title = "Cladribine monotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma",
abstract = "Cladribine is a purine analogue that is resistant to degradation by adenosine deaminase. We describe the efficacy of cladribine monotherapy in 8 patients with relapsed or refractory indolent non-Hodgkin lymphoma. The median age of the patients was 57 years. All patients were given 1-3 courses of cladribine monotherapy at 0.09 mg/kg/day continuous infusion for 7 days. Although all patients had been treated with rituximab and CHOP-like regimens, the response rate was excellent (85.7{\%}). Thus we consider that cladribine is the first treatment of choice in the patients with relapsed or refractory indolent lymphoma.",
author = "Yasuhiro Nakashima and Toshihiro Shimada and Y. Yamada and Ilseung Choi and Yuji Yufu and Naokuni Uike",
year = "2004",
month = "1",
day = "1",
language = "English",
volume = "45",
pages = "568--570",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "7",

}

TY - JOUR

T1 - Cladribine monotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma

AU - Nakashima, Yasuhiro

AU - Shimada, Toshihiro

AU - Yamada, Y.

AU - Choi, Ilseung

AU - Yufu, Yuji

AU - Uike, Naokuni

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Cladribine is a purine analogue that is resistant to degradation by adenosine deaminase. We describe the efficacy of cladribine monotherapy in 8 patients with relapsed or refractory indolent non-Hodgkin lymphoma. The median age of the patients was 57 years. All patients were given 1-3 courses of cladribine monotherapy at 0.09 mg/kg/day continuous infusion for 7 days. Although all patients had been treated with rituximab and CHOP-like regimens, the response rate was excellent (85.7%). Thus we consider that cladribine is the first treatment of choice in the patients with relapsed or refractory indolent lymphoma.

AB - Cladribine is a purine analogue that is resistant to degradation by adenosine deaminase. We describe the efficacy of cladribine monotherapy in 8 patients with relapsed or refractory indolent non-Hodgkin lymphoma. The median age of the patients was 57 years. All patients were given 1-3 courses of cladribine monotherapy at 0.09 mg/kg/day continuous infusion for 7 days. Although all patients had been treated with rituximab and CHOP-like regimens, the response rate was excellent (85.7%). Thus we consider that cladribine is the first treatment of choice in the patients with relapsed or refractory indolent lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=6944220205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6944220205&partnerID=8YFLogxK

M3 - Article

C2 - 15359918

AN - SCOPUS:6944220205

VL - 45

SP - 568

EP - 570

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 7

ER -